SLXNW

distress 8/10 · high distress / dilution risk

$0.03+34%today-1% from 52w high

silexion.com13 employeesFounded 2008Jerusalem, Israel

Lead: locally advanced pancreatic cancer · est. market ~$5B (approx, global)

Revenue

pre-revenue

Liquidity

$2M

Runway

0.2 yrs

Shares 1y

+473%

Price & events

+27.0% over 6M

CatalystRating changeDilutionFinancingdashed = today

+33.6%

+0.0%

—

+27.0%

All

Overview

Market Cap: $139.94K
Volume: 0
52 Week Range: $0.03 – $0.03
Total Shares: 4.19M
Float Shares: 414.62K
Beta: -0.26

Pipeline · 0 trials · 0 upcoming

Readout	Phase	Drug	Indication	Enroll	Status
No pipeline trials tracked.

Catalyst news & presentations · 2

2025-12-16regulatory submissionFiled (NDA/BLA)SIL204 · Submitted CTA to Israel for Phase 2/3 trialSEC 8-K
2025-12-02fda agreementPositive feedback from German health authority on Phase 2/3 trial design for pancreatic cancer.SEC 8-K

Approved drugs (0)

none — clinical-stage

Capital structure — dilution & financing

Shares out: 4,189,954 · 8 offerings/1y · 3 PIPEs

2026-06-18424B3offering
2026-06-18EFFECTshelf_effective
2026-06-12S-3shelf_registration
2026-05-158-Kprivate_placement
2026-05-11EFFECTshelf_effective
2026-05-11EFFECTshelf_effective
2025-10-31S-3shelf_registration

🔒 Positioning — Pro

Short interest / days-to-cover, insider buys & sells.

Upgrade to Pro

🔒 Top holders — Pro

Institutional ownership + quarter-over-quarter accumulation/trimming.

Upgrade to Pro

Wall St ratings

no consensus

no recent rating changes

Competitors — locally advanced pancreatic cancer

RNXTRenovoRx, Inc.$39M · D5
SLXNSilexion Therapeutics Corp$10M · D6